Bio-Rad Laboratories (BIO-B) Cash & Equivalents (2009 - 2026)

Bio-Rad Laboratories (BIO-B) has 18 years of Cash & Equivalents data on file, last reported at $507.2 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $507.2 million, down 2.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $507.2 million (down 2.72% YoY), and the FY2025 annual result was $529.8 million, up 8.54% from the prior year.
• Cash & Equivalents retreated to $507.2 million in Q1 2026 per BIO-B's latest filing, from $529.8 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $802.3 million in Q1 2022 and troughed at $369.3 million in Q2 2025.
• A 5-year average of $478.2 million and a median of $457.8 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents slumped 42.15% in 2023, then gained 20.88% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $434.2 million in 2022, then fell by 7.0% to $403.8 million in 2023, then increased by 20.88% to $488.1 million in 2024, then rose by 8.54% to $529.8 million in 2025, then dropped by 4.27% to $507.2 million in 2026.
• Business Quant data shows BIO-B's Cash & Equivalents at $507.2 million in Q1 2026, $529.8 million in Q4 2025, and $395.8 million in Q3 2025.